FDCDDQ
JNCE

Federation des caisses Desjardins du Quebec’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,226
Closed -$207K – 2195
2017
Q3 		$207K Buy
13,226
+7,462
+129% +$105K ﹤0.01% 1007
2017
Q2 		$80.9K Buy
+5,764
New +$123K ﹤0.01% 1271

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's JNCE Position: Q4 2017 in Review

Federation des caisses Desjardins du Quebec sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2017, closing a stake of 13,226 shares — an estimated $207K sold.

Federation des caisses Desjardins du Quebec first reported a position in JNCE in Q2 2017 and held it in 2 quarters. The position peaked at $207K in Q3 2017. 83 funds tracked by Wall St. Rank hold JNCE as of Q4 2017.

  • Federation des caisses Desjardins du Quebec reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 13,226 Jounce Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $207K.
  • Federation des caisses Desjardins du Quebec first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • Federation des caisses Desjardins du Quebec's Jounce Therapeutics, Inc. Common Stock position peaked at $207K in Q3 2017.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2017, filed 30 Aug 2024.